Nanjing Vazyme Biotech Co (SHSE:688105) Short-Term Debt: ¥525 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688105 Nanjing Vazyme Biotech Co Ltd SHSE:688105
74 GF Score
Price ¥19.62
GF Value ¥21.34
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Nanjing Vazyme Biotech Co Short-Term Debt?

Nanjing Vazyme Biotech Co SHSE:688105 +0.62% 74 Short-Term Debt is ¥525 Mil as of Jun. 2026. GuruFocus rates SHSE:688105 with a GF Score™ of 74/100 and a GF Value™ of ¥21.34 (Fairly Valued). The stock has 2 warning signs investors should review.

Nanjing Vazyme Biotech Co's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥525 Mil.

Nanjing Vazyme Biotech Co's quarterly Short-Term Debt increased from Dec. 2025 (¥687 Mil) to Mar. 2026 (¥858 Mil) but then declined from Mar. 2026 (¥858 Mil) to Jun. 2026 (¥525 Mil).

Nanjing Vazyme Biotech Co's annual Short-Term Debt declined from Dec. 2023 (¥1,134 Mil) to Dec. 2024 (¥551 Mil) but then increased from Dec. 2024 (¥551 Mil) to Dec. 2025 (¥687 Mil).

Nanjing Vazyme Biotech Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Nanjing Vazyme Biotech Co Short-Term Debt Related Terms

Nanjing Vazyme Biotech Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Nanjing Vazyme Biotech Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Vazyme Biotech Co Short-Term Debt Chart

Nanjing Vazyme Biotech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only 0.00 272.21 1,133.96 551.32 686.68

Nanjing Vazyme Biotech Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 935.45 696.36 686.68 858.43 525.27
SHSE:688105
74GF Score
Nanjing Vazyme Biotech Co Ltd SHSE:688105
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥525 Mil mean?
Nanjing Vazyme Biotech Co (SHSE:688105) has a Short-Term Debt of ¥525 Mil as of Jun. 2026.
Is Nanjing Vazyme Biotech Co's Short-Term Debt too high?
Nanjing Vazyme Biotech Co's current Short-Term Debt is ¥525 Mil. Overall, Nanjing Vazyme Biotech Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Vazyme Biotech Co's Short-Term Debt compare to VRTX and REGN?
Nanjing Vazyme Biotech Co's Short-Term Debt of ¥525 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Nanjing Vazyme Biotech Co's current Short-Term Debt is ¥525 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Vazyme Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Vazyme Biotech Co (SHSE:688105) is currently considered Fairly Valued. The stock's GF Value™ is ¥21.34, compared to a current price of ¥19.62 — trading 8.1% below its estimated fair value. The current Short-Term Debt is ¥525 Mil. Nanjing Vazyme Biotech Co's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Nanjing Vazyme Biotech Co (SHSE:688105), the current Short-Term Debt is ¥525 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanjing Vazyme Biotech Co (SHSE:688105) Overvalued in 2026?

Based on GuruFocus' analysis, Nanjing Vazyme Biotech Co stock appears to be undervalued. The current stock price of ¥19.62 is trading 8.1% below its estimated GF Value™ of ¥21.34. GuruFocus considers Nanjing Vazyme Biotech Co to be Fairly Valued.

Key valuation signals for SHSE:688105:

  • Short-Term Debt: ¥525 Mil
  • GF Value™: ¥21.34 vs. price of ¥19.62 (8.1% below fair value)
  • GF Score™: 74/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanjing Vazyme Biotech Co Business Description

Address Kechuang Road, Floor 1-6, East Section, Building C1-2, Hongfeng Science and Technology Park, Jiangsu, Economic and Technological Development Zone, Nanjing, CHN, 210000
Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.
74GF Score

Get the complete analysis for SHSE:688105

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥19.62
Price
¥21.34
GF Value